DR. YAO-TSENG CHEN, M.D.
Medical Practice at 68 St, New York, NY
License number
New York 184134
Category
Medical Practice
Type
Specialist
Address
Address
525 E 68Th St, New York, NY 10065
Phone
(646) 253-2808
(212) 746-3856 (Fax)
(212) 746-3856 (Fax)
Personal information
See more information about YAO-TSENG CHEN at radaris.comName
Address
Phone
New York, NY
Organization information
See more information about YAO-TSENG CHEN at bizstanding.comYao-Tseng Chen MD
525 E 68 St, New York, NY 10065
Categories:
Pathology Physicians & Surgeons, Physicians & Surgeons
Phone:
(212) 746-6472 (Phone)
Professional information
Isolated Nucleic Acid Molecule Encoding An Esophageal Cancer Associated Antigen, The Antigen Itself, And Uses Thereof
US Patent:
6069233, May 30, 2000
Filed:
Jan 26, 1998
Appl. No.:
9/013150
Inventors:
Yao-tseng Chen - New York NY
Matthew Scanlan - New York NY
Ali O. Gure - New York NY
Lloyd J. Old - New York NY
Ozlem Tureci - Homburg/Saar, DE
Ugur Sahin - Homburg/Saar, DE
Michael Pfreundschuh - Homburg/Saar, DE
Matthew Scanlan - New York NY
Ali O. Gure - New York NY
Lloyd J. Old - New York NY
Ozlem Tureci - Homburg/Saar, DE
Ugur Sahin - Homburg/Saar, DE
Michael Pfreundschuh - Homburg/Saar, DE
Assignee:
Memorial Sloan-Kettering Cancer Center - New York NY
Cornell Research Foundation - Ithaca NY
Ludwig Institute for Cancer Research - New York NY
Cornell Research Foundation - Ithaca NY
Ludwig Institute for Cancer Research - New York NY
International Classification:
C07K 14435
US Classification:
530350
Abstract:
The invention relates to the isolation of a nucleic acid molecule which encodes an esophageal cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen.
Yao-Tseng Chen, New York NY
Specialties:
Pathologist
Address:
525 E 68Th St, New York, NY 10065
Education:
Cornell University - Doctor of Philosophy
National Taiwan University, College of Medicine - Doctor of Medicine
National Taiwan University, College of Medicine - Doctor of Medicine
Board certifications:
American Board of Pathology Certification in Clinical Pathology (Pathology)
Isolated Nucleic Acid Molecule Encoding An Esophageal Cancer Associated Antigen
US Patent:
6255470, Jul 3, 2001
Filed:
Sep 14, 1999
Appl. No.:
9/396184
Inventors:
Yao-tseng Chen - New York NY
Matthew Scanlan - New York NY
Ali Gure - New York NY
Lloyd J. Old - New York NY
Matthew Scanlan - New York NY
Ali Gure - New York NY
Lloyd J. Old - New York NY
Assignee:
Memorial Sloan-Kettering Cancer Center - New York NY
International Classification:
C12N 1511, C07H 2104, C12Q 168
US Classification:
536 231
Abstract:
The invention relates to the isolation of a nucleic acid molecule which encodes an esophageal cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen.
Isolated Peptides Corresponding To Amino Acid Sequences Of Ny-Eso-1, Which Bind To Mhc Class I And Mhc Class Ii Molecules, And Uses Thereof
US Patent:
6723832, Apr 20, 2004
Filed:
Oct 2, 1998
Appl. No.:
09/165546
Inventors:
Alexander Knuth - Frankfurt am Main, DE
Elke Jäger - Frankfurt am Main, DE
Yao-tseng Chen - New York NY
Matthew Scanlan - New York NY
Ali Gure - New York NY
Gerd Ritter - New York NY
Lloyd J. Old - New York NY
Jan W. Drijfhout - Leiden, NL
Elke Jäger - Frankfurt am Main, DE
Yao-tseng Chen - New York NY
Matthew Scanlan - New York NY
Ali Gure - New York NY
Gerd Ritter - New York NY
Lloyd J. Old - New York NY
Jan W. Drijfhout - Leiden, NL
Assignee:
Ludwig Institute for Cancer Research - New York NY
Memorial Sloan-Kettering Cancer Center - New York NY
Academisch Ziekenhuis Leiden - Leiden
Cornell Research Foundation - Ithaca NY
Memorial Sloan-Kettering Cancer Center - New York NY
Academisch Ziekenhuis Leiden - Leiden
Cornell Research Foundation - Ithaca NY
International Classification:
C07K 700
US Classification:
530324, 530325, 530326, 530328, 530350, 514 12, 514 13, 514 15, 514885, 4241851, 424450, 424 851, 424 852, 4242821, 4242831
Abstract:
The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
Compositions Containing A P53 Derived Protein Or Peptide, An Adjuvant, And Interleukin-12 And Uses Thereof
US Patent:
6355256, Mar 12, 2002
Filed:
Mar 22, 1995
Appl. No.:
08/408915
Inventors:
Yuji Noguchi - New York NY
Yao-tseng Chen - New York NY
Lloyd J. Old - New York NY
Yao-tseng Chen - New York NY
Lloyd J. Old - New York NY
Assignee:
Ludwig Institute for Cancer Research - New York NY
Memorial Sloan Kettering Cancer Center - New York NY
Memorial Sloan Kettering Cancer Center - New York NY
International Classification:
A61K 3900
US Classification:
4242771, 424 91, 424 92, 424 852, 4241841, 4242781, 4242791
Abstract:
The invention involves the combination of Interleukin-12 with p53 derived peptides and an adjuvant, preferably QS-21. It is found that this combination provokes a surprisingly strong immune response. Further, in an accepted in vivo model, the use of compositions containing these three ingredients led to diamatic decreases in the growth of induced tumors, thus suggesting a therapeutic regime.
Method For Inducing Cell Lysis With Immunogenic Portions Of Ny-Eso-1 Protein
US Patent:
8541202, Sep 24, 2013
Filed:
Feb 24, 2012
Appl. No.:
13/404633
Inventors:
Alexander Knuth - Frankfurt am Main, DE
Elke Jäger - Frankfurt am Main, DE
Yao-tseng Chen - New York NY, US
Matthew Scanlan - New York NY, US
Ali Gure - New York NY, US
Gerd Ritter - New York NY, US
Lloyd J. Old - New York NY, US
Jan W. Drijfhout - Leiden, NL
Elke Jäger - Frankfurt am Main, DE
Yao-tseng Chen - New York NY, US
Matthew Scanlan - New York NY, US
Ali Gure - New York NY, US
Gerd Ritter - New York NY, US
Lloyd J. Old - New York NY, US
Jan W. Drijfhout - Leiden, NL
Assignee:
Ludwig Institute for Cancer Research - New York NY
International Classification:
C12P 21/02, C12N 15/09, C12N 15/12, C12N 15/63, C12N 1/21, C07H 21/04
US Classification:
435 691, 43525233, 4353201, 536 235
Abstract:
The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
Tumor Rejection Antigen Precursor
US Patent:
5843448, Dec 1, 1998
Filed:
Nov 17, 1995
Appl. No.:
8/560024
Inventors:
Yao-Tseng Chen - New York NY
Elisabeth Stockert - New York NY
Yachi Chen - New York NY
Pilar Garin-Chesa - Biberach, DE
Wolfgang J. Rettig - Biberach, DE
Lloyd J. Old - New York NY
Elisabeth Stockert - New York NY
Yachi Chen - New York NY
Pilar Garin-Chesa - Biberach, DE
Wolfgang J. Rettig - Biberach, DE
Lloyd J. Old - New York NY
Assignee:
Ludwig Institute of Cancer Research - New York NY
International Classification:
A61K 3810, A61K 3900, C07K 708, C07K 1482
US Classification:
4241851
Abstract:
The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule MAGE-1, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of MAGE-1, peptides which are useful as immunogens, and immunogenic compositions containing the peptides and an adjuvant.
Monoclonal Antibodies Which Bind To Tumor Rejection Antigen Precursor Mage-1
US Patent:
5541104, Jul 30, 1996
Filed:
Feb 1, 1994
Appl. No.:
8/190411
Inventors:
Yao-Tseng Chen - New York NY
Elisabeth Stockert - New York NY
Yachi Chen - New York NY
Pilar Garin-Chesa - Biberach, DE
Wolfgang J. Rettig - Biberach, DE
Pierre van der Bruggen - Brussels, BE
Thierry Boon-Falleur - Brussels, BE
Lloyd J. Old - New York NY
Elisabeth Stockert - New York NY
Yachi Chen - New York NY
Pilar Garin-Chesa - Biberach, DE
Wolfgang J. Rettig - Biberach, DE
Pierre van der Bruggen - Brussels, BE
Thierry Boon-Falleur - Brussels, BE
Lloyd J. Old - New York NY
Assignee:
Ludwig Institute for Cancer Research - New York NY
Cornell Research Foundation, Inc. - Ithaca NY
Cornell Research Foundation, Inc. - Ithaca NY
International Classification:
C12P 2104, C12P 2108, C12N 500, C07K 1600
US Classification:
43524027
Abstract:
The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule MAGE-1, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of MAGE-1, peptides which are useful as immunogens, and immunogenic compositions containing the peptides and an adjuvant.
Isolated Nucleic Acid Molecules Encoding Eso-1 Peptides And Uses Thereof
US Patent:
7291335, Nov 6, 2007
Filed:
Dec 17, 2001
Appl. No.:
10/023182
Inventors:
Elisabeth Stockert - New York NY, US
Elke Jäger - Frankfurt am Main, DE
Yao-tseng Chen - New York NY, US
Matthew Scanlan - New York NY, US
Alexander Knuth - Frankfurt am Main, DE
Lloyd J. Old - New York NY, US
Elke Jäger - Frankfurt am Main, DE
Yao-tseng Chen - New York NY, US
Matthew Scanlan - New York NY, US
Alexander Knuth - Frankfurt am Main, DE
Lloyd J. Old - New York NY, US
Assignee:
Ludwig Institute for Cancer Research - New York NY
International Classification:
A61K 39/00
US Classification:
4241841, 4241851, 530300, 530350
Abstract:
The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.
Method For Inducing Cell Lysis With Immunogenic Portions Of Ny-Eso-1 Protein
US Patent:
8142786, Mar 27, 2012
Filed:
Jan 10, 2011
Appl. No.:
12/930522
Inventors:
Alexander Knuth - Frankfurt am Main, DE
Elke Jäger - Frankfurt am Main, DE
Yao-tseng Chen - New York NY, US
Matthew Scanlan - New York NY, US
Ali Gure - New York NY, US
Gerd Ritter - New York NY, US
Lloyd J. Old - New York NY, US
Jan W. Drijfhout - Leiden, NL
Elke Jäger - Frankfurt am Main, DE
Yao-tseng Chen - New York NY, US
Matthew Scanlan - New York NY, US
Ali Gure - New York NY, US
Gerd Ritter - New York NY, US
Lloyd J. Old - New York NY, US
Jan W. Drijfhout - Leiden, NL
Assignee:
Ludwig Institute for Cancer Research - New York NY
International Classification:
A61K 38/08, A61K 38/20, C07K 7/00
US Classification:
4241851, 4242781, 530328
Abstract:
The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.